AAPL back to $250
AAPL made money with phones, but now losing its lead. Just like Blackberry dropped from over a hundred to 6 AAPL will drop to 250 maybe even less. What is really left without the phones?
That puts Amgen, the world’s largest biotechnology company by revenue, ahead by six months to a year of its closest competitor in the drug class, a compound being developed by Sanofi (SAN) and Regeneron Pharmaceuticals Inc. (REGN), according to Eric Schmidt, an analyst with Cowen & Co. He estimates Amgen’s drug may target as many as 17 million patients in the U.S., Europe and Japan.
“My race is really getting this to patients as fast as we possibly can,” Sean Harper, head of research and development at Amgen, said in a telephone interview. “It’s a substantial global unmet need.”
Analysts estimate Amgen’s drug could draw more than $1 billion in sales in 2018, and getting to market before competitors may tip the scales in the company’s favor.
Actually no, I got frustrated and sold my rather large position, moving the money somewhere else. I revisited REGN and contemplated buying the dips, but then I noticed the news about momo stock and a possible future distribution...so for the moment I'm just on the side lines
Pump and dump
I'm still holding a sizable amount of share due to the dividend, but I'm not as comfortable as 3 month ago. There are more unfavorable article popping up everywhere, but some analysts are stating that the negatives such as over-capacity are overstated and the drillers will bounce back
Decent earnings, but the problem is that the whisper numbers where too high and now Wall Street is disappointed. It could be a little bump in the road, maybe a buying opportunity.
There are so many opportunities out there, Bio Tech is still strong, look at REGN, AMGN, BIIB, CLG. You could have made a fortune while you wasted your time on this junk
Those who wanted an iphone already ordered from competitor. Stock still dropping in after hours trading
Before long the price target for BAC will be lifted to at 27 - 30. They are capable of generating 12% to 13% returns over time, then they should be trading trading at close to 2 times tangible book value improved from 1.2 today.
Maxim Group’s Jason Kolbert upped his target for Gilead Sciences (GILD) today, based on potential sales of Sovaldi.
Kolbert, who rates Gilead Sciences a Buy, raised his price target to $98 from $89.